Clinical trial NCT03113071: Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Official title: A Phase Ib/II Study of the Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Lead sponsor: Fox Chase Cancer Center
Sponsor class: OTHER
First posted: 2017-04-13
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.

For Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1.
Primary purpose: TREATMENT

Brief summary: The primary hypothesis is that digoxin can be safely added to decitabine and will increase the response rates in medically unfit patients with newly diagnosed AML/MDS or those with relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to decitabine will result in distinct epigenetic alterations in AML/MDS patients.


Eligibility criteria: Inclusion Criteria:

1. Patients must have a confirmed diagnosis of one of the following:

   * Newly diagnosed AML (excluding APL)
   * Newly diagnosed intermediate-2 (INT-2) or high-risk MDS
   * Relapsed or Refractory AML, or INT-2 or high-risk MDS
2. For patients with refractory disease they must be at least 4 weeks out from most recent therapeutic intervention.
3. Age \> 18 years.
4. ECOG performance status 0 - 2.
5. Patients must have normal organ function as defined below:

   * Total bilirubin within normal institutional limits
   * AST/ALT (SGOT/SGPT) \< 2 times institutional normal limits
   * Creatinine within normal institutional limits OR
   * Creatinine clearance \> 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
6. Ability to understand and willingness to sign a written informed consent and HIPAA consent document.
7. Agreement on the part of any male participant to use effective contraception during sexual activity throughout the duration of treatment and for 2 months after discontinuation, for protection against the risk of embryofetal toxicity.

Exclusion Criteria:

1. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events (less than or equal to Grade 1 toxicity) due to agents administered more than 4 weeks earlier.
2. Patients receiving any other investigational agents.
3. Patients with known brain metastases, active infection, or untreated CNS leukemia.
4. Patients with prior or current history of digoxin exposure.
5. Patients requiring treatment with one or more medications known to interact adversely with digoxin, namely thiazide and/or loop diuretics, quinidine, ritonavir, amiodarone, cyclosporine, itraconazole, propafenone, spironolactone, verapamil.
6. Patients requiring treatment with one or more beta-blockers (metoprolol, atenolol, propranolol) or calcium channel blockers with AV-nodal blocking activity (verapamil, diltiazem).
7. Patient with history of prior exposure to decitabine.
8. Patients eligible for intensive induction chemotherapy and "Medically unfit" based on a TRM score ≥ 13.1\*

   * TRM Score= A scoring model which predicts early death following intensive induction chemotherapy in newly diagnosed AML.

     * Model looks at ECOG PS, Age, Platelet Count, Albumin, 2nd AML, WBC, % Peripheral Blasts, Creatinine
     * Score above 13.1 associated with 31%+ chance of death after induction
9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
10. Known HIV-positive patients on combination anti-retroviral therapy are ineligible because of the potential for pharmacokinetic interactions with digoxin. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.
11. Pregnant or breast feeding

Primary outcomes:
measure: Maximum Tolerated Dose of Digoxin in Combination With Standard Dose of Decitabine in Patients Newly Diagnosed AML/MDS or Those With Relapsed or Refractory AML/MDS Considered Unfit for Induction Therapy
timeFrame: 1-2 months
measure: Number of Grade II and IV Toxicities Due to of the Combination Therapy of Decitabine in Combination With Digoxin
timeFrame: 1-3 years
measure: Number of MDS Patients With Complete Remission (CR)
timeFrame: 1-3 years
measure: Number of AML Patients With Complete Remission With Incomplete Blood Count Recovery (CRi)
timeFrame: 1-3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Philadelphia
country: United States
facility: Jeans Hospital
state: Pennsylvania
Study officials:
References: